Journal
NANOSCALE
Volume 9, Issue 37, Pages 14058-14064Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7nr04990k
Keywords
-
Categories
Funding
- NSFC [51673150]
- International S&T Cooperation Program of China (ISTCP) [2015DFA50310]
- National Program for Support of Topnotch Young Professionals
- Science & Technology Projects of Tianjin of China [15JCZDJC38100]
Ask authors/readers for more resources
Inflammatory responses play crucial roles in the development and progression of tumors. Tumor-associated inflammation not only promotes tumor growth but also induces the suppression of immune responses against tumors. We demonstrate in this study that hydrogels of nonsteroidal anti-inflammatory drug (NSAID) modified D-tetrapeptides (G(D)F(D)F(D)Y) are promising cancer vaccine adjuvants, especially for Fbp-gel and Car-gel. The hydrogels allow easy incorporation of a protein OVA antigen by vortexing. Our results indicate that vaccines based on Fbp-gel and Car-gel increase IgG production by 1476- and 929-fold, compared with the OVA group, respectively. They exhibit higher IgG2a antibody titers and stimulate the production of IFN-gamma and IL-6 cytokines. Their higher antibody and cytokine eliciting properties in combination with their anti-inflammatory properties endow them with excellent tumor elimination properties in vivo. In a preventive immune assay against B16-OVA tumors, they totally prevent tumorigenesis. In a therapeutic immune assay against EG7-OVA tumors, they inhibit tumor growth by 75%, compared with the PBS group. Our results suggest the great potential of our hydrogels in the development of vaccines to treat cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available